This report provides a comprehensive analysis of the global transfusion diagnosis for donor market, projecting steady growth from 2025 through 2032. It examines the complete industrial chain, ranging from biological raw materials to automated screening platforms used by blood banks and hospitals. Key market drivers include rising healthcare expenditures and a significant shift toward molecular-based testing to minimize infection detection window periods. Additionally, the study explores technological trends like AI integration and high-throughput systems while evaluating competitive strategies among leading global manufacturers.

Market Overview

Market Size and Growth

The global Transfusion Diagnosis for Donor market is projected to grow from US$ 4402 million in 2025 to US$ 6479 million in 2032, representing a compound annual growth rate (CAGR) of 5.7% from 2026 to 2032.

Profitability

Major companies within the industry maintain gross profit margins ranging between 50% and 70%.

Industry Definition

Transfusion Diagnosis for Donors refers to the critical medical screening and testing process performed on blood donors to ensure the safety and compatibility of blood products. This process includes:

• Mandatory screening for transfusion-transmitted infections (TTIs): Such as HIV, Hepatitis B and C, and Syphilis, utilizing Nucleic Acid Testing (NAT) and ELISA.
• Blood group serology: Including ABO/Rh typing and cross-matching.

These procedures are fundamental to modern hemovigilance, ensuring every blood unit meets stringent clinical safety standards to prevent adverse reactions in recipients.

Industrial Chain Analysis

• Upstream: Providers of biological raw materials (antigens, antibodies, enzymes), precision optical sensors, microfluidic chips, and high-purity reagents.
• Midstream: Manufacturers of automated blood screening platforms, molecular diagnostic systems, and immunoassays.
• Downstream: National and regional blood centers, hospital blood banks, and plasma collection stations.
• Support Services & Infrastructure:
• Cold-chain logistics providers.
• Regulatory bodies.
• Service providers offering calibration, system maintenance, and integrated blood management software to track blood units from collection to clinical transfusion, ensuring full traceability and safety.

Market Dynamics

Growth Drivers and Trends

• Automation and Molecular Testing: A significant shift toward automated and molecular-based testing is occurring to minimize the "window period" of infection detection.
• Integration of Technologies: A key trend involves the integration of Nucleic Acid Testing (NAT) with traditional serology to enhance sensitivity.
• Digital Transformation: The adoption of Big Data and AI in blood management systems is optimizing inventory and reducing wastage.
• Demographic and Economic Factors: Increasing global healthcare expenditures and aging populations are driving the demand for safe blood supplies.
• Technological Focus: Manufacturers are prioritizing high-throughput systems that reduce manual errors while maintaining the highest levels of diagnostic accuracy and safety.

Market Challenges and Opportunities

• Barriers to Entry: Stringent regulatory requirements pose a high entry barrier for new participants.
• Emerging Markets: The expansion of blood banking infrastructure in emerging economies provides substantial growth opportunities.

Report Scope and Methodology

Research Objectives

This LPI (LP Information) research report, titled “Transfusion Diagnosis for Donor Industry Forecast,” provides a comprehensive analysis of the global landscape. The report covers:

• Historical and Projected Sales: A review of total world Transfusion Diagnosis for Donor sales in 2025 and a detailed analysis of projected sales from 2026 through 2032.
• Strategic Analysis: Evaluation of key trends related to product segmentation, company formation, revenue, market share, latest developments, and M&A activity.
• Competitive Intelligence: Analysis of leading global companies, focusing on their portfolios, capabilities, market entry strategies, market positions, and geographic footprints.
• Nuanced Forecasting: A breakdown of the forecast by type, application, geography, and market size to identify emerging pockets of opportunity.

Methodology

• The study utilizes a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs to offer a highly nuanced view of the current state and future trajectory of the industry.

Market Segmentation

By Type

• Instruments
• Kits and Reagents

By Diagnostic Purpose

• Blood Grouping & Typing Diagnostics
• Infectious Disease Screening Diagnostics

By Testing Method

• Immunoassay-Based Diagnostics
• Molecular Diagnostics

By Application

• Blood Banks
• Blood Donation/Transfusion Centers
• Others

By Geography

• Americas: United States, Canada, Mexico, Brazil
• APAC: China, Japan, Korea, Southeast Asia, India, Australia
• Europe: Germany, France, UK, Italy, Russia
• Middle East & Africa: Egypt, South Africa, Israel, Turkey, GCC Countries

Competitive Landscape

Key companies profiled in this report have been selected based on primary expert input and analysis of their coverage, product portfolio, and market penetration.

Key Players

• Abbott
• AliveDx Holdings Finance
• Atlas Medical GmbH
• BAG Diagnostics GmbH
• Bio-Rad Laboratories
• Diasorin
• F. Hoffmann-La Roche
• Grifols
• Lorne Laboratories
• Prestige Diagnostics
• QuidelOrtho Corporation
• Werfen

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Transfusion Diagnosis for Donor Market Size (2021-2032)

    • 2.1.2 Transfusion Diagnosis for Donor Market Size CAGR by Region (2021 VS 2025 VS 2032)

    • 2.1.3 World Current & Future Analysis for Transfusion Diagnosis for Donor by Country/Region (2021, 2025 & 2032)

  • 2.2 Transfusion Diagnosis for Donor Segment by Type

    • 2.2.1 Instruments

    • 2.2.2 Kits and Reagents

    • 2.2.3 Transfusion Diagnosis for Donor Market Size by Type

      • 2.2.3.1 Transfusion Diagnosis for Donor Market Size CAGR by Type (2021 VS 2025 VS 2032)
      • 2.2.3.2 Global Transfusion Diagnosis for Donor Market Size Market Share by Type (2021-2026)

  • 2.3 Transfusion Diagnosis for Donor Segment by Diagnostic Purpose

    • 2.3.1 Blood Grouping & Typing Diagnostics

    • 2.3.2 Infectious Disease Screening Diagnostics

    • 2.3.3 Transfusion Diagnosis for Donor Market Size by Diagnostic Purpose

      • 2.3.3.1 Transfusion Diagnosis for Donor Market Size CAGR by Diagnostic Purpose (2021 VS 2025 VS 2032)
      • 2.3.3.2 Global Transfusion Diagnosis for Donor Market Size Market Share by Diagnostic Purpose (2021-2026)

  • 2.4 Transfusion Diagnosis for Donor Segment by Testing Method

    • 2.4.1 Immunoassay-Based Diagnostics

    • 2.4.2 Molecular Diagnostics

    • 2.4.3 Transfusion Diagnosis for Donor Market Size by Testing Method

      • 2.4.3.1 Transfusion Diagnosis for Donor Market Size CAGR by Testing Method (2021 VS 2025 VS 2032)
      • 2.4.3.2 Global Transfusion Diagnosis for Donor Market Size Market Share by Testing Method (2021-2026)

  • 2.5 Transfusion Diagnosis for Donor Segment by Application

    • 2.5.1 Blood Banks

    • 2.5.2 Blood Donation/Transfusion Centers

    • 2.5.3 Others

    • 2.5.4 Transfusion Diagnosis for Donor Market Size by Application

      • 2.5.4.1 Transfusion Diagnosis for Donor Market Size CAGR by Application (2021 VS 2025 VS 2032)
      • 2.5.4.2 Global Transfusion Diagnosis for Donor Market Size Market Share by Application (2021-2026)

• 3 Transfusion Diagnosis for Donor Market Size by Player

  • 3.1 Transfusion Diagnosis for Donor Market Size Market Share by Player

    • 3.1.1 Global Transfusion Diagnosis for Donor Revenue by Player (2021-2026)

    • 3.1.2 Global Transfusion Diagnosis for Donor Revenue Market Share by Player (2021-2026)

  • 3.2 Global Transfusion Diagnosis for Donor Key Players Head office and Products Offered

  • 3.3 Market Concentration Rate Analysis

    • 3.3.1 Competition Landscape Analysis

    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.4 New Products and Potential Entrants

  • 3.5 Mergers & Acquisitions, Expansion

• 4 Transfusion Diagnosis for Donor by Region

  • 4.1 Transfusion Diagnosis for Donor Market Size by Region (2021-2026)

  • 4.2 Global Transfusion Diagnosis for Donor Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Transfusion Diagnosis for Donor Market Size Growth (2021-2026)

  • 4.4 APAC Transfusion Diagnosis for Donor Market Size Growth (2021-2026)

  • 4.5 Europe Transfusion Diagnosis for Donor Market Size Growth (2021-2026)

  • 4.6 Middle East & Africa Transfusion Diagnosis for Donor Market Size Growth (2021-2026)

• 5 Americas

  • 5.1 Americas Transfusion Diagnosis for Donor Market Size by Country (2021-2026)

  • 5.2 Americas Transfusion Diagnosis for Donor Market Size by Type (2021-2026)

  • 5.3 Americas Transfusion Diagnosis for Donor Market Size by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Transfusion Diagnosis for Donor Market Size by Region (2021-2026)

  • 6.2 APAC Transfusion Diagnosis for Donor Market Size by Type (2021-2026)

  • 6.3 APAC Transfusion Diagnosis for Donor Market Size by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

• 7 Europe

  • 7.1 Europe Transfusion Diagnosis for Donor Market Size by Country (2021-2026)

  • 7.2 Europe Transfusion Diagnosis for Donor Market Size by Type (2021-2026)

  • 7.3 Europe Transfusion Diagnosis for Donor Market Size by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Transfusion Diagnosis for Donor by Region (2021-2026)

  • 8.2 Middle East & Africa Transfusion Diagnosis for Donor Market Size by Type (2021-2026)

  • 8.3 Middle East & Africa Transfusion Diagnosis for Donor Market Size by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Global Transfusion Diagnosis for Donor Market Forecast

  • 10.1 Global Transfusion Diagnosis for Donor Forecast by Region (2027-2032)

    • 10.1.1 Global Transfusion Diagnosis for Donor Forecast by Region (2027-2032)

    • 10.1.2 Americas Transfusion Diagnosis for Donor Forecast

    • 10.1.3 APAC Transfusion Diagnosis for Donor Forecast

    • 10.1.4 Europe Transfusion Diagnosis for Donor Forecast

    • 10.1.5 Middle East & Africa Transfusion Diagnosis for Donor Forecast

  • 10.2 Americas Transfusion Diagnosis for Donor Forecast by Country (2027-2032)

    • 10.2.1 United States Market Transfusion Diagnosis for Donor Forecast

    • 10.2.2 Canada Market Transfusion Diagnosis for Donor Forecast

    • 10.2.3 Mexico Market Transfusion Diagnosis for Donor Forecast

    • 10.2.4 Brazil Market Transfusion Diagnosis for Donor Forecast

  • 10.3 APAC Transfusion Diagnosis for Donor Forecast by Region (2027-2032)

    • 10.3.1 China Transfusion Diagnosis for Donor Market Forecast

    • 10.3.2 Japan Market Transfusion Diagnosis for Donor Forecast

    • 10.3.3 Korea Market Transfusion Diagnosis for Donor Forecast

    • 10.3.4 Southeast Asia Market Transfusion Diagnosis for Donor Forecast

    • 10.3.5 India Market Transfusion Diagnosis for Donor Forecast

    • 10.3.6 Australia Market Transfusion Diagnosis for Donor Forecast

  • 10.4 Europe Transfusion Diagnosis for Donor Forecast by Country (2027-2032)

    • 10.4.1 Germany Market Transfusion Diagnosis for Donor Forecast

    • 10.4.2 France Market Transfusion Diagnosis for Donor Forecast

    • 10.4.3 UK Market Transfusion Diagnosis for Donor Forecast

    • 10.4.4 Italy Market Transfusion Diagnosis for Donor Forecast

    • 10.4.5 Russia Market Transfusion Diagnosis for Donor Forecast

  • 10.5 Middle East & Africa Transfusion Diagnosis for Donor Forecast by Region (2027-2032)

    • 10.5.1 Egypt Market Transfusion Diagnosis for Donor Forecast

    • 10.5.2 South Africa Market Transfusion Diagnosis for Donor Forecast

    • 10.5.3 Israel Market Transfusion Diagnosis for Donor Forecast

    • 10.5.4 Turkey Market Transfusion Diagnosis for Donor Forecast

  • 10.6 Global Transfusion Diagnosis for Donor Forecast by Type (2027-2032)

  • 10.7 Global Transfusion Diagnosis for Donor Forecast by Application (2027-2032)

    • 10.7.1 GCC Countries Market Transfusion Diagnosis for Donor Forecast

• 11 Key Players Analysis

  • 11.1 Grifols

    • 11.1.1 Grifols Company Information

    • 11.1.2 Grifols Transfusion Diagnosis for Donor Product Offered

    • 11.1.3 Grifols Transfusion Diagnosis for Donor Revenue, Gross Margin and Market Share (2021-2026)

    • 11.1.4 Grifols Main Business Overview

    • 11.1.5 Grifols Latest Developments

  • 11.2 F. Hoffmann-La Roche

    • 11.2.1 F. Hoffmann-La Roche Company Information

    • 11.2.2 F. Hoffmann-La Roche Transfusion Diagnosis for Donor Product Offered

    • 11.2.3 F. Hoffmann-La Roche Transfusion Diagnosis for Donor Revenue, Gross Margin and Market Share (2021-2026)

    • 11.2.4 F. Hoffmann-La Roche Main Business Overview

    • 11.2.5 F. Hoffmann-La Roche Latest Developments

  • 11.3 Abbott

    • 11.3.1 Abbott Company Information

    • 11.3.2 Abbott Transfusion Diagnosis for Donor Product Offered

    • 11.3.3 Abbott Transfusion Diagnosis for Donor Revenue, Gross Margin and Market Share (2021-2026)

    • 11.3.4 Abbott Main Business Overview

    • 11.3.5 Abbott Latest Developments

  • 11.4 Bio-Rad Laboratories

    • 11.4.1 Bio-Rad Laboratories Company Information

    • 11.4.2 Bio-Rad Laboratories Transfusion Diagnosis for Donor Product Offered

    • 11.4.3 Bio-Rad Laboratories Transfusion Diagnosis for Donor Revenue, Gross Margin and Market Share (2021-2026)

    • 11.4.4 Bio-Rad Laboratories Main Business Overview

    • 11.4.5 Bio-Rad Laboratories Latest Developments

  • 11.5 Werfen

    • 11.5.1 Werfen Company Information

    • 11.5.2 Werfen Transfusion Diagnosis for Donor Product Offered

    • 11.5.3 Werfen Transfusion Diagnosis for Donor Revenue, Gross Margin and Market Share (2021-2026)

    • 11.5.4 Werfen Main Business Overview

    • 11.5.5 Werfen Latest Developments

  • 11.6 QuidelOrtho Corporation

    • 11.6.1 QuidelOrtho Corporation Company Information

    • 11.6.2 QuidelOrtho Corporation Transfusion Diagnosis for Donor Product Offered

    • 11.6.3 QuidelOrtho Corporation Transfusion Diagnosis for Donor Revenue, Gross Margin and Market Share (2021-2026)

    • 11.6.4 QuidelOrtho Corporation Main Business Overview

    • 11.6.5 QuidelOrtho Corporation Latest Developments

  • 11.7 AliveDx Holdings Finance

    • 11.7.1 AliveDx Holdings Finance Company Information

    • 11.7.2 AliveDx Holdings Finance Transfusion Diagnosis for Donor Product Offered

    • 11.7.3 AliveDx Holdings Finance Transfusion Diagnosis for Donor Revenue, Gross Margin and Market Share (2021-2026)

    • 11.7.4 AliveDx Holdings Finance Main Business Overview

    • 11.7.5 AliveDx Holdings Finance Latest Developments

  • 11.8 BAG Diagnostics GmbH

    • 11.8.1 BAG Diagnostics GmbH Company Information

    • 11.8.2 BAG Diagnostics GmbH Transfusion Diagnosis for Donor Product Offered

    • 11.8.3 BAG Diagnostics GmbH Transfusion Diagnosis for Donor Revenue, Gross Margin and Market Share (2021-2026)

    • 11.8.4 BAG Diagnostics GmbH Main Business Overview

    • 11.8.5 BAG Diagnostics GmbH Latest Developments

  • 11.9 Diasorin

    • 11.9.1 Diasorin Company Information

    • 11.9.2 Diasorin Transfusion Diagnosis for Donor Product Offered

    • 11.9.3 Diasorin Transfusion Diagnosis for Donor Revenue, Gross Margin and Market Share (2021-2026)

    • 11.9.4 Diasorin Main Business Overview

    • 11.9.5 Diasorin Latest Developments

  • 11.10 Prestige Diagnostics

    • 11.10.1 Prestige Diagnostics Company Information

    • 11.10.2 Prestige Diagnostics Transfusion Diagnosis for Donor Product Offered

    • 11.10.3 Prestige Diagnostics Transfusion Diagnosis for Donor Revenue, Gross Margin and Market Share (2021-2026)

    • 11.10.4 Prestige Diagnostics Main Business Overview

    • 11.10.5 Prestige Diagnostics Latest Developments

  • 11.11 Atlas Medical GmbH

    • 11.11.1 Atlas Medical GmbH Company Information

    • 11.11.2 Atlas Medical GmbH Transfusion Diagnosis for Donor Product Offered

    • 11.11.3 Atlas Medical GmbH Transfusion Diagnosis for Donor Revenue, Gross Margin and Market Share (2021-2026)

    • 11.11.4 Atlas Medical GmbH Main Business Overview

    • 11.11.5 Atlas Medical GmbH Latest Developments

  • 11.12 Lorne Laboratories

    • 11.12.1 Lorne Laboratories Company Information

    • 11.12.2 Lorne Laboratories Transfusion Diagnosis for Donor Product Offered

    • 11.12.3 Lorne Laboratories Transfusion Diagnosis for Donor Revenue, Gross Margin and Market Share (2021-2026)

    • 11.12.4 Lorne Laboratories Main Business Overview

    • 11.12.5 Lorne Laboratories Latest Developments

• 12 Research Findings and Conclusion